Hall Capital Management Co. Inc. increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,780 shares of the medical research company’s stock after buying an additional 220 shares during the period. Hall Capital Management Co. Inc.’s holdings in Thermo Fisher Scientific were worth $923,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in TMO. Pitcairn Co. increased its position in shares of Thermo Fisher Scientific by 1.3% in the 2nd quarter. Pitcairn Co. now owns 16,871 shares of the medical research company’s stock worth $3,495,000 after purchasing an additional 215 shares during the last quarter. Nvwm LLC increased its position in shares of Thermo Fisher Scientific by 6.1% in the 2nd quarter. Nvwm LLC now owns 4,231 shares of the medical research company’s stock worth $877,000 after purchasing an additional 242 shares during the last quarter. Tiedemann Advisors LLC increased its position in shares of Thermo Fisher Scientific by 19.4% in the 2nd quarter. Tiedemann Advisors LLC now owns 1,518 shares of the medical research company’s stock worth $315,000 after purchasing an additional 247 shares during the last quarter. Chesapeake Wealth Management increased its position in shares of Thermo Fisher Scientific by 6.0% in the 2nd quarter. Chesapeake Wealth Management now owns 4,393 shares of the medical research company’s stock worth $910,000 after purchasing an additional 249 shares during the last quarter. Finally, Middleton & Co Inc MA increased its position in shares of Thermo Fisher Scientific by 2.3% in the 3rd quarter. Middleton & Co Inc MA now owns 11,123 shares of the medical research company’s stock worth $2,715,000 after purchasing an additional 250 shares during the last quarter. 85.22% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE:TMO opened at $243.45 on Friday. The company has a quick ratio of 1.27, a current ratio of 1.84 and a debt-to-equity ratio of 0.66. Thermo Fisher Scientific Inc. has a fifty-two week low of $181.51 and a fifty-two week high of $249.95. The stock has a market cap of $95.91 billion, a P/E ratio of 25.65, a price-to-earnings-growth ratio of 1.73 and a beta of 1.08.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 24th. The medical research company reported $2.62 earnings per share for the quarter, beating analysts’ consensus estimates of $2.55 by $0.07. Thermo Fisher Scientific had a net margin of 10.75% and a return on equity of 16.49%. The business had revenue of $5.92 billion during the quarter, compared to the consensus estimate of $5.70 billion. During the same quarter in the prior year, the firm earned $2.31 EPS. The company’s revenue for the quarter was up 15.7% compared to the same quarter last year. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 11.04 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, January 15th. Shareholders of record on Monday, December 17th will be paid a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 0.28%. The ex-dividend date is Friday, December 14th. Thermo Fisher Scientific’s payout ratio is 7.17%.

Thermo Fisher Scientific declared that its board has initiated a share repurchase plan on Friday, September 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to purchase up to 2.1% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its stock is undervalued.

Several research firms have recently weighed in on TMO. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $261.00 target price for the company in a research report on Monday, August 6th. Leerink Swann boosted their target price on shares of Thermo Fisher Scientific from $239.00 to $255.00 and gave the stock an “outperform” rating in a research report on Thursday, July 26th. ValuEngine raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, July 24th. UBS Group initiated coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, October 9th. They set a “buy” rating and a $295.00 price objective for the company. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $300.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, July 26th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $261.45.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 125,520 shares of the business’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $247.50, for a total transaction of $31,066,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.49% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2018/11/10/hall-capital-management-co-inc-has-923000-position-in-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Read More: What is a Reverse Stock Split?

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.